Company

Product

Description

Indication

Status (Date)

CANCER

GLYCODesign* (Canada)

GD0039

Oral inhibitor of Golgi amannosidase II

Renal cell carcinoma and 5-FU-resistant colorectal cancer

Added third site in Canada (6/22)

Novogen Ltd. (Australia)

NV-06

Synthetic form of a naturally occurring human phenolichormone with anticancer activity

Prostate enlargement and cancer

Presented data from ongoing Australian studies at theAnnual Scientific Meeting of the American Endocrine Society (6/15)

CARDIOVASCULAR

Novogen Ltd. (Australia)

P-081

Combination of four isoflavones derived from an extractof red clover

Increase of high-density lipoprotein and decrease oflow-density lipoprotein in post-menopausal women as a protection againstatherosclerosis

Reported results from Australian trial (6/1)

CENTRAL NERVOUS SYSTEM

Active Biotech AB (Sweden; )

­

Orally active immune regulator

Multiple sclerosis

Swedish Medical Products Agency approved initiation oftrials (6/29)

INFECTION

Maxim Pharmaceuticals Inc.

Maxamine Therapy

H2 receptor agonist that blocks phagocyte signal thatleads to the death of natural killer T cells

Chronic hepatitis C (combination therapy with interferon-alpha)

Initiated Phase II trial in Europe (6/1)

MISCELLANEOUS

Creative Bio-Molecules Inc. and Stryker Corp.(NYSE:SYK)

OP-1 Implant

Device that combines genetically engineered bone morphogenicprotein (OP-1) with resorbable collagen scaffold that is surgically implantedin bone fractures and defects

Long bone nonunions

Submitted marketing authorization application to EuropeanMedicines Evaluation Agency (6/7)

Levotech Inc.*

­

Contraceptive transdermal patch that delivers estrogenand progesterone

Contraception

Completed enrollment in Phase II/III trial (6/22)

Orphan Medical Inc. and Cambridge Laboratories*(U.K.)

Antizol Injection

Fomepizole (4-methylpyrazole); synthetic alcohol dehydrogenaseinhibitor

Antidote for suspected or confirmed ethylene glycol (anti-freezeor coolant) poisoning

Cleared for marketing in the U.K. (6/25)

** Unless otherwise noted, the stock symbols for publiclytraded biotechnology companies are listed on pp. 13 and 14.

* Privately held company